Biotechnology

A landmark grant funds research into scaffold-free tissue, a revolutionary approach that could one day eliminate the need for many knee replacements.

The Jackson Laboratory appoints Steven Holstein to bridge science and capital, supercharging its new integrated platform for developing breakthrough therapies.

French firms Clean Cells and Naobios eye South Korea's booming biopharma sector, offering a rare integrated solution for viral vaccine and therapy development.

A global partnership aims to bring Atla-cel, a next-gen CAR-T therapy with low neurotoxicity, to children with leukaemia, potentially revolutionizing treatment.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Backed by Maria Sharapova, new startup Amulet launches a science-first supplement aiming to optimize women's performance throughout their entire cycle.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

A new partnership introduces PBSerum®, a biologically inspired enzyme treatment, aiming to redefine skin quality in the multi-billion dollar aesthetics market.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

A new study shows the feasibility of a single device for glucose monitoring and insulin delivery, aiming to simplify life for millions with diabetes.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

At analytica 2026, Haier Biomedical unveiled its 'In Europe, For Europe' strategy, challenging market leaders with integrated solutions and local roots.